New York, September 25, 2024: Qure.ai, a global healthcare AI innovator, has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the US market and other geographies, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

The Series D round saw the participation of new strategic and financial investors led by Lightspeed and 360 ONE Asset, joined by Merck Global Health Innovation Fund and Kae Capital. Existing investors also participated in the round, including Novo Holdings, HealthQuad, and TeamFund.

Founded in 2016, Qure.ai is on a mission to make healthcare more accessible and equitable globally. This has driven its AI solution development, positioning the company as the world’s most deployed healthcare AI. Qure.ai solutions are deployed in over 90 countries across 3000+ sites, powering the efficient identification and management of critical diseases. The company has 18 FDA-cleared indications, and its products are Class IIb certified per EU MDR* regulations. Qure.ai is headquartered in Mumbai, with regional offices in New York, London, and Dubai.

“Qure.ai has become a trusted medical imaging AI partner to hospitals and healthcare organizations around the world. Our work is helping to unlock clinical efficiencies and drive up the standard of care delivered to patients in the focus areas of TB, Lung Cancer and Stroke,” said Prashant Warier, Co-founder and CEO of Qure.ai. “AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes to workforce resource constraints, not just in western societies like the US and Europe, but in developing nations too. We also collaborate with half of the top 20 Pharma and MedTech companies including AstraZeneca, Medtronic, and J&J, to accelerate early diagnosis and timely treatment of diseases. This Series D round is an exciting step forward in our journey and will propel us forward in our mission to reach a billion patients through our solutions.”

Dev Khare, Partner at Lightspeed said, “We are excited to back Prashant and his exceptional team at Qure.ai, a true leader in AI-driven healthcare diagnostics. With diagnostic specificity and sensitivity at levels rivalling radiologists and physicians, Qure is making quality healthcare accessible in the US and Europe as well as globally in Asia, Africa and Latin America.”

“We are thrilled to partner with Qure.ai on its mission to revolutionize patient care for critical conditions like TB, Lung Cancer, and Stroke. We believe that most meaningful impact of AI can be in healthcare and Qure is leading the way in making that a reality. Its work on helping detect and diagnose TB in real-time in low-resource and high-disease burden regions across the world has the potential for massive impact. In high-mortality diseases like Lung Cancer, by enabling earlier diagnosis and treatment, Qure can be transformational in improving clinical outcomes. We look forward to joining Prashant and his team in the next exciting phase of the growth journey,” said Tarun Sharma, Fund Manager at 360 ONE Asset. 

About Qure.ai

Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Stroke to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.  

For Media Queries

Georgina Wright – georgina.wright@qure.ai

Amrutha Joseph – amrutha.joseph@qure.ai

About Lightspeed

Lightspeed is a global multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, Health, and Fintech sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 500 companies globally including Affirm, Acceldata, Carta, Cato Networks, Darwinbox Epic Games, Faire, Innovaccer, Guardant Health, Mulesoft, Navan, Netskope, Nutanix, Rubrik, Sharechat, Snap, OYO Ultima Genomics and more. Lightspeed and its global team currently manage over $25B in AUM across the Lightspeed platform, with investment professionals and advisors in the U.S., Europe, India, Israel, and Southeast Asia. www.lsip.com

About 360 ONE Asset

360 ONE Asset Management Limited, earlier known as IIFL Asset Management Limited, is among India’s leading alternates-focused and public markets-focused firms, offering products across multiple asset classes. With deep domain knowledge, a strong understanding of the Indian markets and a highly experienced investment team, 360 ONE Asset is focused on creating the right risk-adjusted alpha for investors. 

About Merck Global Health Innovation Fund

Merck Global Health Innovation Fund (MGHIF) is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care.

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.